Sangeeta N. Bhatia Vertex Pharmaceuticals Inc (VRTX) insider trading activity

VRTX Quotes by TradingView

Sangeeta N. Bhatia is Director of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 4,435 shares of VRTX, which is worth approximately $2.15 Million. The most recent transaction as insider was on Aug 30, 2024, when has been sold 646 shares (Common Stock) at a price of $500.0 per share, resulting in proceeds of $323,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.44K
0% 3M change
1.12% 12M change
Total Value Held $2.15 Million

Sangeeta N. Bhatia Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 30 2024
SELL
Open market or private sale
$323,000 $500.0 p/Share
646 Reduced 12.71%
4,435 Common Stock
Aug 30 2024
BUY
Exercise of conversion of derivative security
$98,670 $152.74 p/Share
646 Added 11.28%
5,081 Common Stock
Aug 08 2024
SELL
Open market or private sale
$602,446 $466.29 p/Share
1,292 Reduced 22.56%
4,435 Common Stock
Aug 08 2024
BUY
Exercise of conversion of derivative security
$197,340 $152.74 p/Share
1,292 Added 18.41%
5,727 Common Stock
May 02 2024
SELL
Open market or private sale
$188,177 $402.95 p/Share
467 Reduced 9.53%
4,435 Common Stock
May 01 2024
BUY
Grant, award, or other acquisition
-
1,001 Added 16.96%
4,902 Common Stock
Oct 17 2023
SELL
Open market or private sale
$91,125 $375.0 p/Share
243 Reduced 5.86%
3,901 Common Stock
Oct 06 2023
SELL
Open market or private sale
$87,120 $360.0 p/Share
242 Reduced 5.52%
4,144 Common Stock
Aug 09 2023
SELL
Open market or private sale
$83,613 $345.51 p/Share
242 Reduced 5.23%
4,386 Common Stock
May 02 2023
SELL
Open market or private sale
$202,048 $348.36 p/Share
580 Reduced 11.14%
4,628 Common Stock
May 01 2023
BUY
Grant, award, or other acquisition
-
1,168 Added 18.32%
5,208 Common Stock
Oct 24 2022
SELL
Open market or private sale
$192,510 $310.0 p/Share
621 Reduced 13.32%
4,040 Common Stock
Aug 08 2022
SELL
Open market or private sale
$181,934 $292.97 p/Share
621 Reduced 11.76%
4,661 Common Stock
Jul 29 2022
SELL
Open market or private sale
$173,619 $279.58 p/Share
621 Reduced 10.52%
5,282 Common Stock
May 02 2022
SELL
Open market or private sale
$191,480 $259.81 p/Share
737 Reduced 11.1%
5,903 Common Stock
May 01 2022
BUY
Grant, award, or other acquisition
-
1,449 Added 17.91%
6,640 Common Stock
Apr 08 2022
SELL
Open market or private sale
$534,341 $280.2 p/Share
1,907 Reduced 26.87%
5,191 Common Stock
Apr 08 2022
BUY
Exercise of conversion of derivative security
$239,729 $125.71 p/Share
1,907 Added 21.18%
7,098 Common Stock
Jun 02 2021
SELL
Open market or private sale
$117,384 $209.99 p/Share
559 Reduced 9.72%
5,191 Common Stock
May 01 2021
BUY
Grant, award, or other acquisition
-
1,842 Added 24.26%
5,750 Common Stock
Oct 05 2020
SELL
Open market or private sale
$2,793,996 $265.69 p/Share
10,516 Reduced 72.91%
3,908 Common Stock
Oct 05 2020
BUY
Exercise of conversion of derivative security
$1,105,790 $126.68 p/Share
8,729 Added 37.7%
14,424 Common Stock
SNB

Sangeeta N. Bhatia

Director
Boston, MA

Track Institutional and Insider Activities on VRTX

Follow VERTEX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

News

Receive news related to VERTEX PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on VRTX